drug

Org 34517

ORG 34517
MeSH C526064
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Merck Sharp & Dohme LLC
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)
NCT00212797Phase 2Completed
Safety Study of ORG 34517 for Major Depression With Psychotic Features
NCT00226278Phase 2Completed

KOLs & investigators

1
James H Kocsis, MD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Merck Sharp & Dohme LLC
company
trial
A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)
PHASE2
trial
Safety Study of ORG 34517 for Major Depression With Psychotic Features
PHASE2
trial
indication
Depression
indication
Depressive Disorder, Major
indication
Depressive Disorder
indication
Depression
indication
KOL
James H Kocsis, MD
KOL score —
person